Stock DNA
Pharmaceuticals & Biotechnology
CNY 8,040 Million (Mid Cap)
16.00
NA
4.24%
-0.33
16.00%
2.57
Revenue and Profits:
Net Sales:
521 Million
(Quarterly Results - Jun 2025)
Net Profit:
182 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
11.61%
0%
11.61%
6 Months
4.23%
0%
4.23%
1 Year
15.76%
0%
15.76%
2 Years
-17.67%
0%
-17.67%
3 Years
22.24%
0%
22.24%
4 Years
14.2%
0%
14.2%
5 Years
13.86%
0%
13.86%
Guilin Sanjin Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.79%
EBIT Growth (5y)
3.53%
EBIT to Interest (avg)
19.95
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.60
Tax Ratio
18.53%
Dividend Payout Ratio
67.60%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.16%
ROE (avg)
12.69%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
2.57
EV to EBIT
14.91
EV to EBITDA
11.80
EV to Capital Employed
3.36
EV to Sales
3.35
PEG Ratio
0.34
Dividend Yield
4.24%
ROCE (Latest)
22.52%
ROE (Latest)
16.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
520.90
461.10
12.97%
Operating Profit (PBDIT) excl Other Income
223.10
147.50
51.25%
Interest
0.00
4.50
-100.00%
Exceptional Items
3.70
0.40
825.00%
Consolidate Net Profit
182.00
104.80
73.66%
Operating Profit Margin (Excl OI)
377.10%
262.20%
11.49%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 12.97% vs -23.86% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 73.66% vs -23.89% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,156.80
2,134.30
1.05%
Operating Profit (PBDIT) excl Other Income
606.70
584.80
3.74%
Interest
14.10
16.70
-15.57%
Exceptional Items
4.70
1.30
261.54%
Consolidate Net Profit
521.50
421.30
23.78%
Operating Profit Margin (Excl OI)
222.60%
215.60%
0.70%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1.05% vs 10.95% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 23.78% vs 27.86% in Dec 2023
About Guilin Sanjin Pharmaceutical Co., Ltd. 
Guilin Sanjin Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






